Cargando…
Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors
BCR-ABL1-negative myeloproliferative neoplasms are burdened by a reduced life expectancy mostly due to an increased risk of thrombo-hemorrhagic events, fibrotic progression/leukemic evolution, and infectious complications. In these clonal myeloid malignancies, JAK2V617F is the main driver mutation,...
Autores principales: | Cattaneo, Daniele, Iurlo, Alessandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639501/ https://www.ncbi.nlm.nih.gov/pubmed/34867980 http://dx.doi.org/10.3389/fimmu.2021.750346 |
Ejemplares similares
-
JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation
por: Pandey, Garima, et al.
Publicado: (2022) -
Targeting cistrome and dysregulated transcriptome of post-MPN sAML
por: Verstovsek, Srdan, et al.
Publicado: (2017) -
P1029: JAK2-CHIP IS ASSOCIATED WITH SIMILAR RISK OF CARDIOVASCULAR DISEASE AS JAK2-MPN
por: Grevet, Jeremy, et al.
Publicado: (2023) -
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
por: Palandri, Francesca, et al.
Publicado: (2023) -
Breakthrough infections in MPN-COVID vaccinated patients
por: Barbui, Tiziano, et al.
Publicado: (2022)